Access
To read this story in full you will need to login or make a payment (see right).
News and Views
Nature Medicine 9, 257 - 258 (2003)
doi:10.1038/nm0303-257
Cancer T cell therapy expands
Brian Becknell1 & Michael A. Caligiuri2
- Integrated Biomedical Science Graduate Program, Department of Internal Medicine, Division of Human Cancer Genetics, Department of Molecular Virology, Immunology & Medical Genetics, College of Medicine and Public Health and The Comprehensive Cancer Center, The Ohio State University, Columbus, Ohio, USA
- Division of Hematology/Oncology, Department of Internal Medicine, Division of Human Cancer Genetics, Department of Molecular Virology, Immunology & Medical Genetics, College of Medicine and Public Health and The Comprehensive Cancer Center, The Ohio State University, Columbus, Ohio, USA
Correspondence to: Michael A. Caligiuri2 e-mail: caligiuri-1@medctr.osu.edu
Abstract
Coaxing T cells into attacking tumors is an intelligent approach to cancer therapy that has met with limited success. A new study applies some very persuasive techniques (pages 279–286).
The genetic engineering of a cancer patient's T lymphocytes is an attractive strategy to specifically redirect T-cell cytotoxicity toward tumor cells. Harnessing these cells of the adaptive immune system for tumor clearance, however, is not without its attendant challenges.
To read this story in full you will need to login or make a payment (see right).
|
MORE ARTICLES LIKE THIS These links to content published by NPG are automatically generated REFERENCE REVIEWS NEWS AND VIEWS RESEARCH |
